{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:38:58Z","timestamp":1792460338564,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clevidipine and nicardipine are commonly used intravenous calcium channel blockers for the management of hypertensive crises. However, comparative evidence regarding their efficacy and safety remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis of randomized controlled trials and observational studies comparing intravenous clevidipine and nicardipine in adults with hypertensive crises. The primary outcome was achievement of target blood pressure reduction. Secondary outcomes included medication volume and blood pressure over-reduction. Random-effects models were used, and certainty of evidence was assessed using the GRADE framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three studies involving 599 patients were included. Clevidipine and nicardipine demonstrated comparable achievement of target blood pressure reduction (OR 0.96, 95% CI 0.48\u20131.94; I\u00b2 = 60%; very low-certainty evidence). Clevidipine was associated with lower odds of blood pressure over-reduction (OR 0.44, 95% CI 0.21\u20130.93; I\u00b2 = 0%) and lower medication volume (MD\u2009\u2212\u2009258.43 mL, 95% CI\u2009\u2212\u2009313.38 to \u2212\u2009203.48 mL; I\u00b2 = 0%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clevidipine and nicardipine demonstrated comparable efficacy in achieving target blood pressure reduction in hypertensive crises. Although clevidipine was associated with lower odds of blood pressure over-reduction and lower medication volume, the evidence base was limited and the certainty of evidence for the primary outcome was very low. These findings should be interpreted cautiously and considered hypothesis-generating until confirmed by larger, high-quality randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-026-06345-z","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:52:38Z","timestamp":1784865158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clevidipine vs. nicardipine in hypertensive crisis: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Hassaan","family":"Abid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Mohamin Abbas","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina Zia","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bisma","family":"Tasawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimsha","family":"Adnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohana","family":"Memon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaaitri","family":"Lohano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Jawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Vazaym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Junaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"2","key":"6345_CR1","first-page":"174","volume":"35","author":"SS O\u2019Connell","year":"2026","unstructured":"O\u2019Connell SS, Whelton PK, Mills KT. Global trends in hypertension prevalence, awareness, treatment, and control. Curr Opin Nephrol Hypertens. 2026;35(2):174\u201380. 10. 1097\/MNH.0000000000001151 PubMed PMID: 41495934; PubMed Central PMCID: PMC13181835.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"6345_CR2","unstructured":"Hypertensive Crisis -. StatPearls - NCBI Bookshelf. [cited 2026 Jan 12]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507701\/."},{"key":"6345_CR3","doi-asserted-by":"publisher","unstructured":"Carey RM, Whelton PK, ACC\/AHA Hypertension Guideline Writing Committee. 2017. Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology\/American Heart Association Hypertension Guideline. Ann Intern Med. 2018;168(5):351\u20138. https:\/\/doi.org\/10.7326\/M17-3203.\u00a0 PubMed PMID: 29357392.","DOI":"10.7326\/M17-3203"},{"issue":"7","key":"6345_CR4","doi-asserted-by":"publisher","first-page":"504","DOI":"10.11909\/j.issn.1671-5411.2018.07.007","volume":"15","author":"A Alshami","year":"2018","unstructured":"Alshami A, Romero C, Avila A, Varon J. Management of hypertensive crises in the elderly. J Geriatr Cardiol. 2018;15(7):504\u201312. https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2018.07.007 . PubMed PMID: 30364798; PubMed Central PMCID: PMC6198269.","journal-title":"J Geriatr Cardiol"},{"issue":"4","key":"6345_CR5","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/j.jemermed.2024.04.006","volume":"67","author":"C Storey","year":"2024","unstructured":"Storey C, Pouliot J. Evaluation of the Efficacy and Safety of Nicardipine Versus Clevidipine for Blood Pressure Control in Hypertensive Crisis. J Emerg Med. 2024;67(4):e368\u201374. https:\/\/doi.org\/10.1016\/j.jemermed.2024.04.006.","journal-title":"J Emerg Med"},{"issue":"2","key":"6345_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40256-021-00494-6","volume":"22","author":"B Xu","year":"2022","unstructured":"Xu B, Chen Z, Tang G. The Current Role of Clevidipine in the Management of Hypertension. Am J Cardiovasc Drugs. 2022;22(2):127\u201339. https:\/\/doi.org\/10.1007\/s40256-021-00494-6 . PubMed PMID: 34472038.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"6345_CR7","doi-asserted-by":"publisher","first-page":"aakag005","DOI":"10.1093\/esj\/aakag","volume":"11","author":"MA Jumaa","year":"2026","unstructured":"Jumaa MA, Gharaibeh K, Burgess RE, Rao R, Oliver MJ, Mierzwa A, et al. Clevidipine infusion for blood pressure management after successful revascularisation in acute ischaemic stroke: the CLEVER study. Eur Stroke J. 2026;11(2):aakag005. https:\/\/doi.org\/10.1093\/esj\/aakag. 005 PubMed PMID: 41701757; PubMed Central PMCID: PMC12911921.","journal-title":"Eur Stroke J"},{"key":"6345_CR8","doi-asserted-by":"publisher","first-page":"107644","DOI":"10.1016\/j.clineuro.2023.107644","volume":"227","author":"A Seifi","year":"2023","unstructured":"Seifi A, Azari Jafari A, Mirmoeeni S, Shah M, Azari Jafari M, Nazari S, et al. Comparison between clevidipine and nicardipine in cerebrovascular diseases: A systematic review and meta-analysis. Clin Neurol Neurosurg. 2023;227:107644. https:\/\/doi.org\/10.1016\/j.clineuro.2023.107644.","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"6345_CR9","doi-asserted-by":"publisher","first-page":"6355","DOI":"10.1038\/s41598-024-54667-9","volume":"14","author":"M Widiastuti","year":"2024","unstructured":"Widiastuti M, Bisri DY, Rachman IA. The safety and efficacy of clevidipine for blood pressure management in neurocritical patients: a systematic review and meta-analysis. Sci Rep. 2024;14(1):6355. https:\/\/doi.org\/10.1038\/s41598-024-54667-9.","journal-title":"Sci Rep"},{"key":"6345_CR10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n. 71 PubMed PMID: 33782057; PubMed Central PMCID: PMC8005924.","journal-title":"BMJ"},{"key":"6345_CR11","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898. PMID: 31462531.","DOI":"10.1136\/bmj.l4898"},{"issue":"9","key":"6345_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135. https:\/\/doi.org\/10.1007\/s10654-010-9491-z.","journal-title":"Eur J Epidemiol"},{"issue":"21","key":"6345_CR13","doi-asserted-by":"publisher","first-page":"e668","DOI":"10.1093\/ajhp\/zxae156","volume":"81","author":"L Johnson","year":"2024","unstructured":"Johnson L, Erdman M, Ferreira J. Comparison of clevidipine vs nicardipine in the treatment of hypertensive urgency and emergency in critically ill patients. Am J Health-System Pharm. 2024;81(21):e668\u201376. https:\/\/doi.org\/10.1093\/ajhp\/zxae156.","journal-title":"Am J Health-System Pharm"},{"issue":"1","key":"6345_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/HJH.0000000000004180","volume":"44","author":"Q Lv","year":"2026","unstructured":"Lv Q, Chen C, Lin L, Zhao X, Chen J, Liang Z, et al. Efficacy and safety of clevidipine emulsion injection compared with nicardipine in patients with hypertensive emergencies: a randomized, single-blind, positive-parallel-controlled, phase III clinical trial. J Hypertens. 2026;44(1):204\u201310. https:\/\/doi.org\/10.1097\/HJH.0000000000004180.","journal-title":"J Hypertens"},{"issue":"4","key":"6345_CR15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1097\/00000542-200004000-00016","volume":"92","author":"H Ericsson","year":"2000","unstructured":"Ericsson H, Bredberg U, Eriksson U, Jolin-Mellg\u00e5rd \u00c5, Nordlander M, Reg\u00e5rdh CG. Pharmacokinetics and Arteriovenous Differences in Clevidipine Concentration following a Short- and a Long-term Intravenous Infusion in Healthy Volunteers. Anesthesiology. 2000;92(4):993\u20131001. https:\/\/doi.org\/10.1097\/00000542-200004000-00016.","journal-title":"Anesthesiology"},{"key":"6345_CR16","doi-asserted-by":"publisher","unstructured":"Writing Committee Members*, Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC et al. \/NMA\/PCNA\/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;152(11). https:\/\/doi.org\/10.1161\/CIR.0000000000001356","DOI":"10.1161\/CIR.0000000000001356"},{"issue":"2","key":"6345_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12028-016-0349-4","volume":"26","author":"JR Finger","year":"2017","unstructured":"Finger JR, Kurczewski LM, Brophy GM. Clevidipine Versus Nicardipine for Acute Blood Pressure Reduction in a Neuroscience Intensive Care Population. Neurocrit Care. 2017;26(2):167\u201373. https:\/\/doi.org\/10.1007\/s12028-016-0349-4.","journal-title":"Neurocrit Care"},{"issue":"8","key":"6345_CR18","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.03.001","volume":"27","author":"Z Rosenfeldt","year":"2018","unstructured":"Rosenfeldt Z, Conklen K, Jones B, Ferrill D, Deshpande M, Siddiqui FM. Comparison of Nicardipine with Clevidipine in the Management of Hypertension in Acute Cerebrovascular Diseases. J Stroke Cerebrovasc Dis. 2018;27(8):2067\u201373. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2018.03.001.","journal-title":"J Stroke Cerebrovasc Dis"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06345-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06345-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06345-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:45:24Z","timestamp":1792457124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06345-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6345"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-06345-z","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is a systematic review and meta-analysis of previously published data; therefore, ethical approval was not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"942"}}